Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 0.75
-0.186 %
$ 17.9 M
Market Cap
-0.51
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
46.34%
EBIT
Estimate
23.58%
Net Income
Estimate
75.11%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
ProPhase Labs, Inc.
PRPH has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart PRPH
EBIT FORECAST
EBIT Forecast Chart PRPH
NET INCOME FORECAST
Net Income Chart PRPH